VETERE, GUGLIELMO
 Distribuzione geografica
Continente #
EU - Europa 47
NA - Nord America 24
AS - Asia 18
AF - Africa 4
Totale 93
Nazione #
IT - Italia 43
US - Stati Uniti d'America 24
SG - Singapore 15
CI - Costa d'Avorio 3
CN - Cina 2
AT - Austria 1
FI - Finlandia 1
IN - India 1
PL - Polonia 1
SE - Svezia 1
SN - Senegal 1
Totale 93
Città #
Florence 6
New York 6
Singapore 6
Genoa 4
Palermo 4
Abidjan 3
Kent 3
Ogden 3
Livorno 2
Lucca 2
Modena 2
Pisa 2
Salerno 2
Turin 2
Dakar 1
Hyderabad 1
Los Angeles 1
Mazzin 1
Milan 1
Mugnano di Napoli 1
Naples 1
Vienna 1
Warsaw 1
Totale 56
Nome #
Colorectal neoplastic emergencies in immunocompromised patients: preliminary result from the Web-based International Register of Emergency Surgery and Trauma (WIRES-T trial) 37
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 19
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 19
FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases 17
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 5
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 4
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors 3
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 3
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 2
Circulating microRNA analysis in a prospective co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer 1
Totale 110
Categoria #
all - tutte 559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 559


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202322 0 0 0 0 0 1 0 1 7 0 13 0
2023/202488 3 3 5 5 9 7 9 6 5 6 21 9
Totale 110